984 related articles for article (PubMed ID: 34798898)
1. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
3. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Kumagai S; Koyama S; Itahashi K; Tanegashima T; Lin YT; Togashi Y; Kamada T; Irie T; Okumura G; Kono H; Ito D; Fujii R; Watanabe S; Sai A; Fukuoka S; Sugiyama E; Watanabe G; Owari T; Nishinakamura H; Sugiyama D; Maeda Y; Kawazoe A; Yukami H; Chida K; Ohara Y; Yoshida T; Shinno Y; Takeyasu Y; Shirasawa M; Nakama K; Aokage K; Suzuki J; Ishii G; Kuwata T; Sakamoto N; Kawazu M; Ueno T; Mori T; Yamazaki N; Tsuboi M; Yatabe Y; Kinoshita T; Doi T; Shitara K; Mano H; Nishikawa H
Cancer Cell; 2022 Feb; 40(2):201-218.e9. PubMed ID: 35090594
[TBL] [Abstract][Full Text] [Related]
4. Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis.
Li Y; Wang Z; Lin H; Wang L; Chen X; Liu Q; Zuo Q; Hu J; Wang H; Guo J; Xie L; Tang J; Li Z; Hu L; Xu L; Zhou X; Ye L; Huang Q; Xu L
Front Immunol; 2020; 11():806. PubMed ID: 32477338
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional repressor Blimp1 regulates follicular regulatory T-cell homeostasis and function.
Yang G; Yang X; Zhang J; Li G; Zheng D; Peng A; Hu J; Xu L; Yang B; Yang H; Zhou W; Tuzun E; Li J
Immunology; 2018 Jan; 153(1):105-117. PubMed ID: 28833081
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of Effector and Regulatory T cell function by Blimp1.
Bankoti R; Ogawa C; Nguyen T; Emadi L; Couse M; Salehi S; Fan X; Dhall D; Wang Y; Brown J; Funari V; Tang J; Martins GA
Sci Rep; 2017 Sep; 7(1):12078. PubMed ID: 28935958
[TBL] [Abstract][Full Text] [Related]
7. Curcumin analog GO-Y030 boosts the efficacy of anti-PD-1 cancer immunotherapy.
MaruYama T; Kobayashi S; Shibata H; Chen W; Owada Y
Cancer Sci; 2021 Dec; 112(12):4844-4852. PubMed ID: 34529884
[TBL] [Abstract][Full Text] [Related]
8. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.
Kugel CH; Douglass SM; Webster MR; Kaur A; Liu Q; Yin X; Weiss SA; Darvishian F; Al-Rohil RN; Ndoye A; Behera R; Alicea GM; Ecker BL; Fane M; Allegrezza MJ; Svoronos N; Kumar V; Wang DY; Somasundaram R; Hu-Lieskovan S; Ozgun A; Herlyn M; Conejo-Garcia JR; Gabrilovich D; Stone EL; Nowicki TS; Sosman J; Rai R; Carlino MS; Long GV; Marais R; Ribas A; Eroglu Z; Davies MA; Schilling B; Schadendorf D; Xu W; Amaravadi RK; Menzies AM; McQuade JL; Johnson DB; Osman I; Weeraratna AT
Clin Cancer Res; 2018 Nov; 24(21):5347-5356. PubMed ID: 29898988
[No Abstract] [Full Text] [Related]
9. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Gyori D; Lim EL; Grant FM; Spensberger D; Roychoudhuri R; Shuttleworth SJ; Okkenhaug K; Stephens LR; Hawkins PT
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875321
[TBL] [Abstract][Full Text] [Related]
10. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
[No Abstract] [Full Text] [Related]
11. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
[TBL] [Abstract][Full Text] [Related]
12. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
[TBL] [Abstract][Full Text] [Related]
13. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
14. Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
Pham CD; Flores C; Yang C; Pinheiro EM; Yearley JH; Sayour EJ; Pei Y; Moore C; McLendon RE; Huang J; Sampson JH; Wechsler-Reya R; Mitchell DA
Clin Cancer Res; 2016 Feb; 22(3):582-95. PubMed ID: 26405194
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells.
Vick SC; Kolupaev OV; Perou CM; Serody JS
J Immunol; 2021 Nov; 207(10):2598-2607. PubMed ID: 34607937
[TBL] [Abstract][Full Text] [Related]
16. Clever-1/stabilin-1 controls cancer growth and metastasis.
Karikoski M; Marttila-Ichihara F; Elima K; Rantakari P; Hollmén M; Kelkka T; Gerke H; Huovinen V; Irjala H; Holmdahl R; Salmi M; Jalkanen S
Clin Cancer Res; 2014 Dec; 20(24):6452-64. PubMed ID: 25320356
[TBL] [Abstract][Full Text] [Related]
17. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas F; Furness AJS; Solomon I; Joshi K; Mekkaoui L; Lesko MH; Miranda Rota E; Dahan R; Georgiou A; Sledzinska A; Ben Aissa A; Franz D; Werner Sunderland M; Wong YNS; Henry JY; O'Brien T; Nicol D; Challacombe B; Beers SA; ; ; ; Turajlic S; Gore M; Larkin J; Swanton C; Chester KA; Pule M; Ravetch JV; Marafioti T; Peggs KS; Quezada SA
Immunity; 2017 Apr; 46(4):577-586. PubMed ID: 28410988
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
19. Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors.
Colbeck EJ; Hindley JP; Smart K; Jones E; Bloom A; Bridgeman H; McPherson RC; Turner DG; Ladell K; Price DA; O'Connor RA; Anderton SM; Godkin AJ; Gallimore AM
Oncotarget; 2015 Sep; 6(28):24649-59. PubMed ID: 26433463
[TBL] [Abstract][Full Text] [Related]
20. Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells.
Kim MJ; Kim K; Park HJ; Kim GR; Hong KH; Oh JH; Son J; Park DJ; Kim D; Choi JM; Lee I; Ha SJ
Nat Immunol; 2023 Jan; 24(1):148-161. PubMed ID: 36577929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
